代謝紊亂治療藥物市場：按疾病類型和產品分類 - 全球預測 2023-2030

全球治療代謝紊亂藥物市場預計將大幅成長，2023年將達到614.1億美元，年複合成長率為8.80%，2030年將達到1,110.4億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球代謝性疾病藥物市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球代謝紊亂治療藥物市場規模及預測為何？

2.在預測期內，COVID-19對全球代謝紊亂治療藥物市場的阻礙因素與影響有哪些？

3.在預測期內，全球代謝紊亂治療藥物市場應投資哪些產品/細分市場/應用/領域？

4.你們在全球代謝性疾病治療藥物市場的競爭策略是什麼？

5.全球代謝性疾病治療藥物市場的技術趨勢和法律規範是什麼？

6.全球代謝性疾病治療藥物市場主要供應商的市佔率為何？

7. 您認為什麼型態和策略性舉措適合進入治療代謝紊亂藥物的全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 提高對代謝性疾病治療的認知
    • 不斷成長的人口中各種代謝疾病的盛行率
    • 改善代謝紊亂的測試和診斷
  • 抑制因素
    • 治療費用高且無法報銷
  • 機會
    • 增加開發新治療方法的資金
    • 基因療法治療代謝性疾病的可能性
  • 任務
    • 嚴格的政府批准的標準和法規
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 代謝紊亂治療藥物市場：依疾病類型

• 糖尿病
• 高膽固醇症
• 溶小體貯積症
• 肥胖

第7章 代謝紊亂治療藥物市場：副產品

• 球狀腦白質營養不良
• 肝性腦病變
• 異染性腦白質營養不良

第8章 北美與南美代謝紊亂治療藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第9章 亞太地區代謝性疾病治療藥物市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第10章 歐洲/中東/非洲代謝紊亂治療藥物市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第11章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

• 討論指南
• 關於許可證和定價

The Global Metabolic Disorders Therapeutics Market is forecasted to grow significantly, with a projected USD 61.41 billion in 2023 at a CAGR of 8.80% and expected to reach a staggering USD 111.04 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Metabolic Disorders Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Metabolic Disorders Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease Type, market is studied across Diabetes, Hypercholesterolemia, Lysosomal Storage Disease, and Obesity. The Hypercholesterolemia is projected to witness significant market share during forecast period.

Based on Product, market is studied across Globoid Leukodystrophy, Hepatic Encephalopathy, and Metachromatic Leukodystrophy. The Globoid Leukodystrophy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Metabolic Disorders Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Metabolic Disorders Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Metabolic Disorders Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Metabolic Disorders Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Metabolic Disorders Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Metabolic Disorders Therapeutics Market?

6. What is the market share of the leading vendors in the Global Metabolic Disorders Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Metabolic Disorders Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Metabolic Disorders Therapeutics Market, by Disease Type, 2022 vs 2030
• 4.3. Metabolic Disorders Therapeutics Market, by Product, 2022 vs 2030
• 4.4. Metabolic Disorders Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing awareness regarding the treatment of metabolic disorders
    • 5.1.1.2. Prevalence of various metabolic diseases in the growing population
    • 5.1.1.3. Improvements in metabolic disorder testing and diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of therapeutics and lack of reimbursements
  • 5.1.3. Opportunities
    • 5.1.3.1. Rise in the funding for the development of novel therapeutic approaches
    • 5.1.3.2. Potential of gene therapy for metabolic disorder treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Strict government approval standards and regulations
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Metabolic Disorders Therapeutics Market, by Disease Type

• 6.1. Introduction
• 6.2. Diabetes
• 6.3. Hypercholesterolemia
• 6.4. Lysosomal Storage Disease
• 6.5. Obesity

7. Metabolic Disorders Therapeutics Market, by Product

• 7.1. Introduction
• 7.2. Globoid Leukodystrophy
• 7.3. Hepatic Encephalopathy
• 7.4. Metachromatic Leukodystrophy

8. Americas Metabolic Disorders Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Metabolic Disorders Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. METABOLIC DISORDERS THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2022 VS 2030 (%)
• FIGURE 5. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
• FIGURE 6. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. METABOLIC DISORDERS THERAPEUTICS MARKET DYNAMICS
• FIGURE 8. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 5. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 10. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 20. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 21. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 33. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 100. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 101. METABOLIC DISORDERS THERAPEUTICS MARKET LICENSE & PRICING